Kidney transplant recipients and the incidence of adverse reactions to cyclosporin.
Tolou-Ghamari
Zahra
Z
Department of Pharmaceutics, Faculty of Pharmacy, University of Medical Sciences and Health Services, Isfahan, Iran. z_tolou_ghamari@hotmail.com
Palizban
Abbas-Ali
AA
D000328:Adult; D000368:Aged; D015331:Cohort Studies; D016572:Cyclosporine / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007492:Iran; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000379:methods; D007683:Kidney Tubular Necrosis, Acute / Q000139:chemically induced*; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods; D011183:Postoperative Complications / Q000175:diagnosis / Q000453:epidemiology; D011446:Prospective Studies; D018570:Risk Assessment; D014181:Transplantation Immunology / Q000187:drug effects*
D007166:Immunosuppressive Agents; D016572:Cyclosporine